Trials / Completed
CompletedNCT03994601
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
A Phase 1/2 First-in-human Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Malignant Tumors
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 219 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether BMS-986288 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of select advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986288 | Specified dose on specified days |
| DRUG | Nivolumab | Specified dose on specified days |
| DRUG | Regorafenib | Specified dose on specified days |
Timeline
- Start date
- 2019-09-06
- Primary completion
- 2024-08-31
- Completion
- 2024-08-31
- First posted
- 2019-06-21
- Last updated
- 2026-01-20
- Results posted
- 2026-01-20
Locations
40 sites across 7 countries: United States, Argentina, Canada, Chile, France, Italy, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03994601. Inclusion in this directory is not an endorsement.